Search
Concizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigational[L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.
Tagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigational[A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigationalHydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis...
Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor
Potassium bitartrate
go.drugbank.com/drugs/DB11107ApprovedInvestigationalPotassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … Approved by the FDA as a direct food substance, potassium bitartrate is used as an additive, stabilizer, pH control agent, antimicrobial agent, processing aid, or thickener in various food products [L2732
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin
Products: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSIONSofpironium
go.drugbank.com/drugs/DB19325Approved[L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis. … [L51109] Soft drugs are designed to reduce systemic toxicity while enhancing local efficacy by employing retrometabolic drug design, in which a molecule contains a metabolically sensitive moiety that promotes
Coagulation Factor IX (Recombinant)
go.drugbank.com/drugs/DB00100ApprovedRecombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. … It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell